KWM
ABBV icon

Keebeck Wealth Management’s AbbVie ABBV Stock Holding History

Keebeck Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.48M Sell
20,604
-3,324
-14% -$737K 0.5% 49
2025
Q4 		$5.47M Sell
23,928
-623
-3% -$142K 0.63% 34
2025
Q3 		$5.68M Sell
24,551
-57
-0.2% -$11.6K 0.67% 38
2025
Q2 		$4.57M Sell
24,608
-548
-2% -$102K 0.6% 46
2025
Q1 		$5.27M Buy
25,156
+148
+0.6% +$28.8K 0.78% 34
2024
Q4 		$4.44M Sell
25,008
-141
-0.6% -$25.9K 0.64% 44
2024
Q3 		$4.97M Sell
25,149
-234
-0.9% -$43.7K 0.72% 40
2024
Q2 		$4.35M Buy
25,383
+8,711
+52% +$1.44M 0.64% 41
2024
Q1 		$3.04M Buy
16,672
+13,380
+406% +$2.31M 0.45% 63
2023
Q4 		$510K Buy
3,292
+77
+2% +$11.2K 0.08% 174
2023
Q3 		$479K Buy
3,215
+168
+6% +$24.7K 0.08% 177
2023
Q2 		$411K Buy
3,047
+35
+1% +$5.13K 0.06% 193
2023
Q1 		$480K Sell
3,012
-716
-19% -$109K 0.08% 165
2022
Q4 		$602K Buy
3,728
+22
+0.6% +$3.37K 0.11% 140
2022
Q3 		$497K Buy
3,706
+8
+0.2% +$1.15K 0.1% 150
2022
Q2 		$566K Buy
3,698
+7
+0.2% +$1.07K 0.11% 146
2022
Q1 		$598K Buy
3,691
+8
+0.2% +$1.16K 0.1% 150
2021
Q4 		$499K Buy
3,683
+312
+9% +$36.9K 0.09% 149
2021
Q3 		$364K Buy
3,371
+8
+0.2% +$914 0.07% 160
2021
Q2 		$379K Sell
3,363
-16,896
-83% -$1.9M 0.05% 188
2021
Q1 		$2.19M Sell
20,259
-114
-0.6% -$12.2K 0.34% 59
2020
Q4 		$2.18M Buy
20,373
+11
+0.1% +$1.06K 0.38% 55
2020
Q3 		$1.78M Buy
20,362
+904
+5% +$85.1K 0.37% 54
2020
Q2 		$1.91M Buy
+19,458
New +$1.71M 0.6% 38
2020
Q1 		– Sell
-2,458
Closed -$217K – 140
2019
Q4 		$217K Buy
+2,458
New +$204K 0.07% 136

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Keebeck Wealth Management's ABBV Position: Q1 2026 in Review

Keebeck Wealth Management reduced its AbbVie (ABBV) stake by 14% in Q1 2026, selling an estimated $737K and leaving 20,604 shares worth $4.48M. The position accounts for 0.5% of the portfolio, ranked #49.

Keebeck Wealth Management first reported a position in ABBV in Q4 2019 and has held it in 25 quarters since. The position peaked at $5.68M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Keebeck Wealth Management held 20,604 shares of AbbVie worth $4.48M as of Q1 2026.
  • Keebeck Wealth Management sold 3,324 AbbVie shares in Q1 2026, an estimated $737K.
  • AbbVie made up 0.5% of Keebeck Wealth Management's portfolio in Q1 2026, its #49 holding.
  • Keebeck Wealth Management first reported a position in AbbVie in Q4 2019 and has held it in 25 quarters since.
  • Keebeck Wealth Management's AbbVie position peaked at $5.68M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Keebeck Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.